Myriad Genetics announces Q2 2026 earnings release date for July 30, 2026
Executive summary: Myriad Genetics announced it will release its Q2 2026 financial results on July 30, 2026, with a conference call scheduled for 4:30 p.m. ET. The earnings release will provide investors with updated financial performance data for the company’s hereditary cancer testing and pharmacogenomics segments, informing investment decisions and market expectations.
Who is involved: Myriad Genetics’ management team, institutional and retail investors, and sell‑side analysts covering the genetics and diagnostics sector.
Likely next: On July 30, 2026 at 4:30 p.m. ET Myriad Genetics will publish its Q2 2026 earnings and host a conference call to discuss the results; analysts will then publish post‑earnings commentary and guidance.
Myriad Genetics announced that it will release its second‑quarter 2026 financial results on July 30, 2026, followed by a conference call at 4:30 p.m. ET. The announcement signals the upcoming disclosure of the company’s financial performance in its genetic testing and precision‑medicine businesses. Investors and analysts will use the results to assess recent trends in hereditary cancer testing and pharmacogenomics demand. No financial figures were disclosed in the notice.
Timeline
- — Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 (GlobeNewswire)
Analysis — what this means
Likely next events
- Myriad Genetics will release its Q2 2026 financial results on July 30, 2026.
- The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
Sectors affected
- Hereditary cancer testing
- Pharmacogenomics
- Precision medicine diagnostics